ABERRANT EXPRESSION OF THE C-ERBB-2/NEU PROTOONCOGENE IN OVARIAN-CANCER

被引:91
|
作者
HUNG, MC [1 ]
ZHANG, X [1 ]
YAN, DH [1 ]
ZHANG, HZ [1 ]
HE, GP [1 ]
ZHANG, TQ [1 ]
SHI, DR [1 ]
机构
[1] SHANGHAI MED UNIV, HOSP CANC, INST CANC, DEPT PATHOL, SHANGHAI 20032, PEOPLES R CHINA
关键词
HER-2; C-ERB-2/NEU; ONCOGENE; OVARIAN CANCER;
D O I
10.1016/0304-3835(92)90166-S
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Overexpression of the c-erbB-2/neu protooncogene has recently been shown in ovarian tumors collected from the United States. It is known that environmental and cultural factors may contribute to certain types of cancer, therefore, we examined expression of c-erbB-2/neu in ovarian tumors collected from China by immunohistochemical staining. Out of 81 tumor specimens, 57 (70.4%) were found to be immunopositive, whereas only one out of 17 (5.9%) normal ovarian tissue samples was slightly positive. Our results indicate that overexpression of c-erbB-2/neu is a general phenomenon for ovarian cancer regardless of different population. To search for a c-erbB/neu overexpressing cell line for future study on molecular mechanism, we also analyzed 13 cancer cell lines from the female genital tract for expression of c-erbB-2/neu. The c-erbB-2/neu RNA was found to be overexpressed at least 100-fold in one of the four ovarian cancer cell lines examined. An aberrant c-erbB-2/neu RNA was also found to be overexpressed in this cell line. Southern blot analysis indicated that the c-erbB-2/neu was amplified 2 - 4-fold in this line, and some of these alleles have structural alteration which may account for expression of the aberrant c-erbB-2/neu RNA. Since the 2 - 4-fold gene amplification is not proportional to the > 100-fold overexpression in RNA, other mechanisms such as transcriptional or post-transcriptional control must be involved in overexpression of this gene in ovarian cancer.
引用
收藏
页码:95 / 103
页数:9
相关论文
共 50 条
  • [1] C-ERBB-2 ONCOGENE EXPRESSION IN OVARIAN-CANCER
    HALDANE, JS
    HIRD, V
    HUGHES, CM
    GULLICK, WJ
    JOURNAL OF PATHOLOGY, 1990, 162 (03): : 231 - 237
  • [2] ORAL-CANCER PROGRESSION AND C-ERBB-2 NEU PROTOONCOGENE EXPRESSION
    HOU, L
    SHI, D
    TU, SM
    ZHANG, HZ
    HUNG, MC
    LING, DH
    CANCER LETTERS, 1992, 65 (03) : 215 - 220
  • [3] AMPLIFICATION OF THE C-ERBB-2(HER-2/NEU) PROTOONCOGENE IN OVARIAN CARCINOMAS
    FAN, QB
    BIAN, ML
    HUANG, SZ
    LANG, JH
    MA, J
    LIU, WS
    XU, XY
    CHINESE MEDICAL JOURNAL, 1994, 107 (08) : 589 - 593
  • [4] SIGNIFICANCE OF C-ERBB-2 AND C-MYC ONCOGENE EXPRESSION FOR PROGNOSIS IN OVARIAN-CANCER
    TANNER, B
    FRIEDBERG, T
    MITZE, M
    KNAPSTEIN, PG
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1993, 254 (1-4) : 946 - 948
  • [5] C-ERBB-2 ONCOGENE EXPRESSION IN STAGE-I EPITHELIAL OVARIAN-CANCER
    LEESON, SC
    MORPHOPOULOS, G
    BUCKLEY, CH
    HALE, RJ
    BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1995, 102 (01): : 65 - 67
  • [6] SERUM LEVELS OF HER-2 NEU (C-ERBB-2) CORRELATE WITH OVEREXPRESSION OF P185(NEU) IN HUMAN OVARIAN-CANCER
    MCKENZIE, SJ
    DESOMBRE, KA
    BAST, BS
    HOLLIS, DR
    WHITAKER, RS
    BERCHUCK, A
    BOYER, CM
    BAST, RC
    CANCER, 1993, 71 (12) : 3942 - 3946
  • [7] EXPRESSION OF THE C-ERBB-2 (NEU) ONCOGENE IN BLADDER-CANCER
    MELLON, K
    NEAL, DE
    WRIGHT, C
    JOHNSTON, P
    CORBETT, IP
    HORNE, CHW
    BRITISH JOURNAL OF CANCER, 1990, 62 (03) : 538 - 538
  • [8] C-ERBB-2 PROTOONCOGENE EXPRESSION AND AMPLIFICATION IN BARRETTS ADENOCARCINOMA
    GRAMLICH, T
    SAMUEL, M
    FRITSCH, C
    GANSLER, T
    COHEN, C
    GASTROENTEROLOGY, 1993, 104 (04) : A407 - A407
  • [9] THE EXPRESSION OF C-ERBB-2 (HER-2/NEU) ONCOGENE IN INVASIVE OVARIAN MALIGNANCIES
    MAKAR, AP
    HOLM, R
    KRISTENSEN, GB
    NESLAND, JM
    TROPE, CG
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1994, 4 (03) : 194 - 199
  • [10] ENHANCED C-ERBB-2/NEU EXPRESSION IN HUMAN OVARIAN-CANCER CELLS CORRELATES WITH MORE SEVERE MALIGNANCY THAT CAN BE SUPPRESSED BY E1A
    YU, DH
    WOLF, JK
    SCANLON, M
    PRICE, JE
    HUNG, MC
    CANCER RESEARCH, 1993, 53 (04) : 891 - 898